sar425899 dual agonist glp-1 glucagon sanofi Media Centre Glucagon agonism in the treatment
Description
Research shows that both are effective and well-tolerated options
17 Periods of protection from patents and exclusivities overlap, and both can block the FDA from approving generic versions of brand-name products
Clinical trials have shown their efficacy and safety over several years, yet the possibility of long-term adverse effects remains a research focus
A., & Drucker, D
ONeil, P.M
As their indications expand, so must our understanding of long-term efficacy, safety, and patient-centered treatment strategies
